Full Press Release Details
| Corporate Relationship Department | National Stock Exchange of India Ltd. |
| BSE Limited | "Exchange Plaza" |
| Dalal Street, Fort | Bandra-Kurla Complex, Bandra (East), |
| Mumbai - 400 001 | Mumbai - 400 051 |
| Fax Nos.: 022-22723121 / 22723719 / | Fax Nos.: 022-26598120/ 26598237/ |
| 22722037 / 22722039 | 26598238 |
| Scrip Code: 500124 | Scrip Code: DRREDDY-EQ |
Please find enclosed two Press Releases
on "Dr. Reddy's Laboratories announces the launch of Redyx in India." and "Dr. Reddy's Laboratories
announces the launch of Over-The-Counter Diclofenac Sodium Topical Gel 1%, the store brand version of Voltaren Arthritis Pain
in the U.S. Market."
This is for your information.
| /s/ Sandeep Poddar | |
| Sandeep Poddar | |
| Company Secretary |
CC:- New York Stock Exchange Inc.(Stock Code :RDY)
| CONTACT | ||
| DR. REDDY'S LABORATORIES LTD. 8-2-337, Road No. 3, Banjara Hills, Hyderabad - 500034. Telangana, India. | Investor relationS | Media relationS |
| AMIT AGARWAL amita@drreddys.com (Ph: +91-40-49002135) | APARNA TEKURI aparnatekuri@drreddys.com (Ph: +91-40- 49002446) |
Laboratories announces the launch of Redyx in India
Hyderabad, India, September 9, 2020 - Dr. Reddy's Laboratories
Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as "Dr. Reddy's")
today announced the launch of Remdesivir, under a brand name Redyx in India. The launch is part of the licensing agreement with
Gilead Sciences, Inc. (Gilead) that grants Dr. Reddy's the right to register, manufacture and sell Remdesivir, a potential
treatment for Covid-19, in 127 countries including India.
Remdesivir is approved by Drug Controller General of India (DCGI)
for restricted emergency use in India for the treatment of Covid-19 patients hospitalized with severe symptoms.
Dr. Reddy's Redyx is available in strength of 100 mg vial.
M V Ramana, Chief Executive Officer, Branded Markets (India
and Emerging Markets), Dr. Reddy's Laboratories, said "We will continue our efforts to develop products that address
significant unmet needs of patients. The launch of Redyx reaffirms our commitment to bringing in critical medicine for patients
suffering from Covid-19 in India."
About Dr. Reddy's: Dr. Reddy's
Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) is an integrated pharmaceutical company, committed to providing affordable
and innovative medicines for healthier lives. Through its three businesses - Pharmaceutical Services & Active Ingredients,
Global Generics and Proprietary Products - Dr. Reddy's offers a portfolio of products and services including APIs,
custom pharmaceutical services, generics, biosimilars and differentiated formulations. Our major therapeutic areas of focus are
gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Dr. Reddy's operates in markets
across the globe. Our major markets include - USA, India, Russia & CIS countries, and Europe. For more information,
log on to: www.drreddys.com
Disclaimer: This press release may include statements
of future expectations and other forward-looking statements that are based on the management's current views and assumptions
and involve known or unknown risks and uncertainties that could cause actual results, performance or events to differ materially
from those expressed or implied in such statements. In addition to statements which are forward-looking by reason of context,
the words "may", "will", "should", "expects", "plans", "intends",
"anticipates", "believes", "estimates", "predicts", "potential", or "continue"
and similar expressions identify forward-looking statements. Actual results, performance or events may differ materially from
those in such statements due to without limitation, (i) general economic conditions such as performance of financial markets,
credit defaults , currency exchange rates, interest rates, persistency levels and frequency / severity of insured loss events,
(ii) mortality and morbidity levels and trends, (iii) changing levels of competition and general competitive factors, (iv) changes
in laws and regulations and in the policies of central banks and/or governments, (v) the impact of acquisitions or reorganization,
including related integration issues, and (vi) the susceptibility of our industry and the markets addressed by our,
and our customers', products and services to economic downturns as a result of natural disasters, epidemics, pandemics or
other widespread illness, including coronavirus (or COVID-19), and (vii) other risks and uncertainties identified in our public
filings with the Securities and Exchange Commission, including those listed under the "Risk Factors" and "Forward-Looking
Statements" sections of our Annual Report on Form 20-F for the year ended March 31, 2020. The company assumes no obligation
to update any information contained herein."
| CONTACT | ||
| DR. REDDY'S LABORATORIES LTD. 8-2-337, Road No. 3, Banjara Hills, Hyderabad - 500034. Telangana, India. | Investor relationS | Media relationS |
| AMIT AGARWAL amita@drreddys.com (Ph: +91-40-49002135) | APARNA TEKURI aparnatekuri@drreddys.com (Ph: +91-40- 49002446) |
Reddy's Laboratories announces the launch of
Over-The-Counter Diclofenac Sodium Topical Gel 1%, the store brand
version of Voltaren Arthritis Pain in the U.S.
Hyderabad, India and Princeton, NJ, USA. September 9, 2020 -
Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as
"Dr. Reddy's") today announced the launch of over-the-counter Diclofenac Sodium Topical Gel 1%, the store brand
version of Voltaren Arthritis Pain in the U.S. market.
"The launch of Dr. Reddy's Diclofenac Sodium Topical
Gel, 1% (OTC), is an important addition to our Pain/ Analgesics portfolio of OTC products, and represents our continued commitment
to the Private Label OTC space," says Marc Kikuchi, CEO, North America Generics, Dr. Reddy's Laboratories. "We
are pleased to partner with Encube Ethicals to bring this product to market for the benefit of consumers."
Dr. Reddy's Diclofenac Sodium Topical Gel, 1%
(OTC), is used for the temporary relief of arthritis pain ONLY in the following areas:
wrist, elbow (upper body areas)
ankle, knee (lower body areas)
Voltaren Arthritis Pain brand had total U.S.
retail sales of approximately $44 million since launch in May 2020 according to IRI*.
Dr. Reddy's Diclofenac Sodium Topical Gel, 1% (OTC), will
soon be available in multiple pack sizes to allow consumers a variety of purchasing options.
Voltaren is a trademark of Novartis Corporation.
*IRI POS TOTAL US - MULO Period ending
About Dr. Reddy's: Dr. Reddy's
Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) is an integrated pharmaceutical company, committed to providing affordable
and innovative medicines for healthier lives. Through its three businesses - Pharmaceutical Services & Active Ingredients,
Global Generics and Proprietary Products - Dr. Reddy's offers a portfolio of products and services including APIs,
custom pharmaceutical services, generics, biosimilars and differentiated formulations. Our major therapeutic areas of focus are
gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Dr. Reddy's operates in markets
across the globe. Our major markets include - USA, India, Russia & CIS countries, and Europe. For more information,
log on to: www.drreddys.com
Disclaimer: This press release may include statements of future
expectations and other forward-looking statements that are based on the management's current views and assumptions and involve
known or unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those
expressed or implied in such statements. In addition to statements which are forward-looking by reason of context, the words "may",
"will", "should", "expects", "plans", "intends", "anticipates", "believes",
"estimates", "predicts", "potential", or "continue" and similar expressions identify forward-looking
statements. Actual results, performance or events may differ materially from those in such statements due to without limitation,
(i) general economic conditions such as performance of financial markets, credit defaults , currency exchange rates, interest rates,
persistency levels and frequency / severity of insured loss events, (ii) mortality and morbidity levels and trends, (iii) changing
levels of competition and general competitive factors, (iv) changes in laws and regulations and in the policies of central banks
and/or governments, (v) the impact of acquisitions or reorganization, including related integration issues, and (vi)
the susceptibility of our industry and the markets addressed by our, and our customers', products and services to economic
downturns as a result of natural disasters, epidemics, pandemics or other widespread illness, including coronavirus (or COVID-19),
and (vii) other risks and uncertainties identified in our public filings with the Securities and Exchange Commission, including
those listed under the "Risk Factors" and "Forward-Looking Statements" sections of our Annual Report on Form
20-F for the year ended March 31, 2020. The company assumes no obligation to update any information contained herein."